Analysis
Bottazzi’s assertion aligns with the World Health Organization’s (WHO) repeated calls for vaccine equity, emphasizing that COVID-19 vaccines should be a *global public good*, not a commodity subject to market forces. The **COVAX initiative**, co-led by WHO, Gavi, and CEPI, was explicitly created to ensure low- and middle-income countries had access to vaccines, reinforcing her point. Her framing of the issue as a *global health priority* over a *business opportunity* is consistent with critiques of vaccine nationalism and patent protections that limited supply in poorer nations. No credible evidence contradicts the ethical or public health basis of her claim.
Background
During the COVID-19 pandemic, disparities in vaccine access became stark, with high-income countries securing doses for their populations while low-income countries faced severe shortages. Bottazzi, a vaccine scientist and co-developer of a patent-free COVID-19 vaccine (CoroVax), has been a vocal advocate for open-access science to address such inequities. The pandemic exposed structural inequalities in global health, prompting debates about intellectual property waivers (e.g., the **TRIPS waiver** discussions at the WTO) and the role of pharmaceutical profits in public health crises.
Verdict summary
Maria Elena Bottazzi’s statement accurately reflects the ethical imperative of equitable COVID-19 vaccine distribution, as widely advocated by global health organizations and experts during the pandemic.